The Role of Long Non-Coding RNA NNT-AS1 in Neoplastic Disease
Medical Genetics Center, School of Medicine, Ningbo University, Ningbo 315211, Zhejiang, China
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(11), 3086; https://doi.org/10.3390/cancers12113086
Received: 19 September 2020
/
Revised: 16 October 2020
/
Accepted: 18 October 2020
/
Published: 23 October 2020
Simple Summary
Nicotinamide nucleotide transhydrogenase-antisense 1 (NNT-AS1), which is a newly-discovered long non-coding RNA (lncRNA), has been found to be dysregulated in a variety of neoplastic diseases. With the accumulation of studies on NNT-AS1 in recent years, the mechanism of NNT-AS1 and its significance for tumor occurrence and progression are constantly being updated and improved. Thus, this paper aims to summarize the abnormal expression of NNT-AS1 and its prognostic values in different neoplastic diseases. In addition, the detailed competing endogenous RNA networks and subsequent biology behaviors, as well as the role of NNT-AS1 in mediating cisplatin resistance are revealed in this paper. This review not only summarizes the past research of NNT-AS1, but also provides some ideas for future research in this field.
Studies have shown that non-coding RNAs (ncRNAs), especially long non-coding RNAs (lncRNAs), play an important regulatory role in the occurrence and development of human cancer. Nicotinamide nucleotide transhydrogenase-antisense 1 (NNT-AS1) is a newly-discovered cytoplasmic lncRNA. Many studies have shown that it has abnormally-high expression levels in malignant tumors, but there are also a few studies that have reported low expression levels of NNT-AS1 in gastric cancer, breast cancer, and ovarian cancer. At present, the regulatory mechanism of NNT-AS1 as a miRNA sponge, which may be an important reason affecting tumor cell proliferation, invasion, metastasis, and apoptosis is being studied in-depth. In addition, NNT-AS1 has been found to be related to cisplatin resistance. In this review, we summarize the abnormal expression of NNT-AS1 in a variety of neoplastic diseases and its diagnostic and prognostic value, and we explain the mechanism by which NNT-AS1 regulates cancer progression by competing with miRNAs. In addition, we also reveal the correlation between NNT-AS1 and cisplatin resistance and the potential clinical applications of NNT-AS1.
View Full-Text
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Zhou, C.; Duan, S. The Role of Long Non-Coding RNA NNT-AS1 in Neoplastic Disease. Cancers 2020, 12, 3086. https://doi.org/10.3390/cancers12113086
AMA Style
Zhou C, Duan S. The Role of Long Non-Coding RNA NNT-AS1 in Neoplastic Disease. Cancers. 2020; 12(11):3086. https://doi.org/10.3390/cancers12113086
Chicago/Turabian StyleZhou, Cong, and Shiwei Duan. 2020. "The Role of Long Non-Coding RNA NNT-AS1 in Neoplastic Disease" Cancers 12, no. 11: 3086. https://doi.org/10.3390/cancers12113086
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
